[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, reported multiple transactions under a Rule 10b5-1 trading plan adopted September 6, 2024. On 09/17/2025 he acquired 79,220 shares of Kymera common stock at $2.08 (via exercise of options) and sold 79,220 shares at a weighted-average price of $50.0048 (sales executed across prices $49.90–$50.25). After the transactions the filing reports 306,629 shares beneficially owned before the sale and 227,409 shares following the sale. The report discloses two stock option transactions with exercise price $2.08 that were fully vested and exercisable, and notes 523 shares were earlier acquired under the employee stock purchase plan on June 2, 2025.

Positive

• Transactions executed under a Rule 10b5-1 plan, providing pre-established timing and compliance clarity
• Options were fully vested and exercisable prior to exercise, as disclosed
• Detailed sale pricing range and weighted-average price provided for transparency
• Form includes prior ESPP acquisition disclosure (523 shares)

Negative

• Large sale of 79,220 shares reduced beneficial ownership from 306,629 to 227,409 shares

Insights

Financial Analyst

TL;DR: Routine insider option exercises and offsetting sales under a 10b5-1 plan; transaction size is disclosed but appears procedural.

The filing documents a common pattern where an executive exercises fully vested options at a low exercise price ($2.08) and sells the resulting shares under a pre-established Rule 10b5-1 plan, realizing proceeds at a weighted-average sale price of $50.0048. The transactions changed beneficial ownership from 306,629 to 227,409 shares. These actions are transparent and accompanied by standard disclosures, including the 10b5-1 plan adoption date and a price range for the multiple sales. From a financial perspective, the exercise and sale crystallize value from long-standing equity compensation rather than signaling an unplanned disposition.

Corporate Governance Expert

TL;DR: Disclosure follows accepted governance practice: use of a 10b5-1 plan and clear footnotes on vesting and sale pricing.

The Form 4 provides required details: reporting person role (CFO), relation to issuer, Rule 10b5-1 plan reference (dated 09/06/2024), and explicit footnotes on vesting and sale pricing across a stated range. It also includes signature and explanatory notes. These elements support compliance with Section 16 reporting norms and reduce ambiguity about timing and intent by tying sales to a pre-authorized trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jacobs Bruce N.

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		M(1)		79,220	A	$2.08	306,629(2)	D
Common Stock	09/17/2025		S(1)		79,220	D	$50.0048(3)	227,409	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	09/17/2025		M(1)			42,246	(4)	08/28/2029	Common Stock	42,246	$0	27,653	D
Stock Option (Right to Buy)	$2.08	09/17/2025		M(1)			36,974	(4)	08/28/2029	Common Stock	36,974	$0	0	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce N. Jacobs	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kymera (KYMR) CFO Bruce Jacobs report on Form 4 dated 09/17/2025?

The filing shows Bruce Jacobs exercised options and acquired 79,220 shares at $2.08 and sold 79,220 shares at a weighted-average $50.0048 under a Rule 10b5-1 plan.

Was the sale by Bruce Jacobs part of a 10b5-1 trading plan for KYMR?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted September 6, 2024.

How did these transactions change Bruce Jacobs' beneficial ownership of KYMR shares?

Beneficial ownership reported moved from 306,629 shares to 227,409 shares following the sale.

What exercise price applied to the stock options Bruce Jacobs exercised?

The stock options exercised had an exercise (conversion) price of $2.08 per share.

Did the Form 4 disclose whether the options were vested?

Yes. The filing states the shares underlying the stock options were fully vested and exercisable.